Scotia Capital Inc. Outlook Therapeutics, Inc. Transaction History

Scotia Capital Inc.

  • $17.8 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024
SELL
$0.22 - $0.66 $11,958 - $35,876
-54,359 Reduced 16.06%
284,080 $110,000
Q3 2023

Nov 14, 2023
BUY
$0.2 - $1.78 $54,692 - $486,764
273,463 Added 420.87%
338,439 $74,000
Q2 2023

Aug 03, 2023
BUY
$1.02 - $1.89 $66,275 - $122,804
64,976 New
64,976 $113,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $317M
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Scotia Capital Inc. Portfolio

Follow Scotia Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scotia Capital Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email